Teprotumumab for the Treatment of Active Thyroid Eye Disease

Douglas Raymond S.; Kahaly G.; Patel Amy; Sile S.; Thompson E. H.; Perdok R.; Fleming J.; Fowler B.; Marcocci C.; Marinò M.; Antonelli A.; Dailey R.; Harris G.; Eckstein A.; Schiffman J.; Tang R.; Nelson C.; Salvi M.; Wester S.; Sherman J.; Vescio T.; Holt R.; Smith Terry J.

doi:10.1056/nejmoa1910434

← Today's brief

RCT

Teprotumumab for the Treatment of Active Thyroid Eye Disease

Douglas Raymond S. et al. · The New England journal of medicine · Wednesday, January 1, 2020

Design Rctn 41Funding Independent

Source

Douglas Raymond S. et al.. Teprotumumab for the Treatment of Active Thyroid Eye Disease. The New England journal of medicine. Wednesday, January 1, 2020.
doi:10.1056/nejmoa1910434Read original ↗

Generated, then checked against the source · how this brief was built →

Sign in to rate and bookmark articles

Automated evidence summary, checked against the source. Not medical advice. Verify with the original publication.